- Home
- IMCR vs CALX Comparison
IMCR vs CALX Comparison
Compare IMCR & CALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CALX
- Stock Information
- Founded
- IMCR 2008
- CALX 1999
- Country
- IMCR United Kingdom
- CALX United States
- Employees
- IMCR N/A
- CALX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CALX Telecommunications Equipment
- Sector
- IMCR Health Care
- CALX Consumer Discretionary
- Exchange
- IMCR Nasdaq
- CALX Nasdaq
- Market Cap
- IMCR 1.6B
- CALX 2.9B
- IPO Year
- IMCR 2021
- CALX 2010
- Fundamental
- Price
- IMCR $35.00
- CALX $50.58
- Analyst Decision
- IMCR Buy
- CALX Strong Buy
- Analyst Count
- IMCR 10
- CALX 6
- Target Price
- IMCR $58.13
- CALX $48.20
- AVG Volume (30 Days)
- IMCR 389.0K
- CALX 630.2K
- Earning Date
- IMCR 08-07-2025
- CALX 07-21-2025
- Dividend Yield
- IMCR N/A
- CALX N/A
- EPS Growth
- IMCR N/A
- CALX N/A
- EPS
- IMCR N/A
- CALX N/A
- Revenue
- IMCR $333,581,000.00
- CALX $825,450,000.00
- Revenue This Year
- IMCR $26.82
- CALX $10.66
- Revenue Next Year
- IMCR $8.15
- CALX $9.99
- P/E Ratio
- IMCR N/A
- CALX N/A
- Revenue Growth
- IMCR 25.75
- CALX N/A
- 52 Week Low
- IMCR $23.15
- CALX $28.61
- 52 Week High
- IMCR $41.54
- CALX $54.07
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- CALX 56.26
- Support Level
- IMCR $32.20
- CALX $51.33
- Resistance Level
- IMCR $35.75
- CALX $54.07
- Average True Range (ATR)
- IMCR 1.31
- CALX 1.25
- MACD
- IMCR 0.28
- CALX -0.21
- Stochastic Oscillator
- IMCR 84.94
- CALX 52.28
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.